Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

ETOP IBCSG Partners Foundation
Sponsor

ETOP IBCSG Partners Foundation

Effingerstrasse 33, 3008

About the sponsor

Research activity includes ER-positive/HER2-negative early breast cancer, operable invasive disease in premenopausal patients, and isolated locoregional recurrence of HR-positive, HER2-negative breast cancer. The portfolio also covers endocrine therapy combinations and post-recurrence treatment strategies.

  • Hormone receptor-positive breast cancer
  • HER2-negative early breast cancer
  • Isolated locoregional recurrence
  • Adjuvant endocrine therapy

Interest extends to treatment approaches that address residual risk after surgery and recurrence patterns in breast cancer.

About Specializations

ETOP IBCSG Partners Foundation runs clinical trials in conditions such as Non-small cell lung cancer, Non-small cell lung cancer stage III, Lung neoplasm malignant, Small cell lung cancer, among others.

Recruiting now

Ongoing trials

Clinical trials run by this sponsor – those enrolling participants first.

Condition
Country
City
Type of trial
Recruitment status
Quick filters

10 clinical trials

Lung neoplasm malignant+2

Recruiting

A study to evaluate the effectiveness of tarlatamab in patients with extensive-stage small cell lung cancer that has progressed after prior treatment and who have limited health status

InvestigationalNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Tarlatamab
  • Sponsor:ETOP IBCSG Partners Foundation

Non-small cell lung cancer+5

Recruiting

Study of cemiplimab treatment after surgery in patients with stage II-IIIA non-small cell lung cancer who have not received chemotherapy and have PD-L1 expression of 1% or higher

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Cemiplimab
  • Sponsor:ETOP IBCSG Partners Foundation

Non-small cell lung cancer+4

Recruiting

Study on the Effects of Adding Durvalumab After Chemotherapy and Surgery in Patients with Resectable Non-Small Cell Lung Cancer

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin
  • Sponsor:ETOP IBCSG Partners Foundation

Non-small cell lung cancer+1

Recruiting

Study of Durvalumab, Tremelimumab, Chemotherapy, and Radiotherapy for Patients with Newly Diagnosed Non-Small Cell Lung Cancer with Limited Spread

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Durvalumab
  • Sponsor:ETOP IBCSG Partners Foundation

Lung neoplasm malignant+2

Recruiting

Study on Niraparib with Immunotherapy for Patients with SLFN11-Positive Extensive-Stage Small Cell Lung Cancer

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Atezolizumab
  • Sponsor:ETOP IBCSG Partners Foundation

EGFR gene mutation+1

Not recruiting

Study on Amivantamab, Lazertinib, and Bevacizumab for Patients with Advanced EGFR-Mutant Non-Small Cell Lung Cancer After Treatment Progression

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Amivantamab
  • Sponsor:ETOP IBCSG Partners Foundation

K-ras gene mutation+1

Not recruiting

Study of adagrasib in elderly patients (70 years or older) or patients with poor performance status who have KRAS G12C mutation-positive non-small cell lung cancer

InvestigationalNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Adagrasib
  • Sponsor:ETOP IBCSG Partners Foundation

Hormone receptor positive breast cancer+2

Not recruiting

Study of palbociclib with hormone therapy versus hormone therapy alone in patients with recurrent hormone receptor-positive/HER2-negative breast cancer after surgery

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Palbociclib
  • Sponsor:ETOP IBCSG Partners Foundation

Non-small cell lung cancer+1

Not recruiting

Study on Brigatinib and Durvalumab for Patients with Unresectable Stage III Non-Small Cell Lung Cancer with ALK Gene Change After Chemotherapy and Radiation Therapy

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Brigatinib
  • Sponsor:ETOP IBCSG Partners Foundation

Hormone receptor positive breast cancer+1

Not recruiting

Study of Giredestrant, Triptorelin, and Anastrozole in Premenopausal Women with ER-Positive/HER2-Negative Early Breast Cancer

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years
  • Substances:Anastrozole
  • Sponsor:ETOP IBCSG Partners Foundation

Are you running a clinical trial?

Increase visibility for your trials and help patients find your site through our platform.

Join now →
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.